Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)

Shoichiro Ohtani,Takahiro Nakayama,Tetsuhiro Yoshinami,Kenichi Watanabe,Fumikata Hara,Yasuaki Sagara,Hidetoshi Kawaguchi,Kenji Higaki,Nobuki Matsunami,Yoshie Hasegawa,Masato Takahashi,Makiko Mizutani,Takashi Morimoto,Masako Sato,Mitsuya Itoh,Satoshi Morita,Norikazu Masuda

Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)

2018

Shoichiro Ohtani
Takahiro Nakayama
Tetsuhiro Yoshinami
Kenichi Watanabe
Fumikata Hara
Yasuaki Sagara
Hidetoshi Kawaguchi
Kenji Higaki
Nobuki Matsunami
Yoshie Hasegawa
Masato Takahashi
Makiko Mizutani
Takashi Morimoto
Masako Sato
Mitsuya Itoh
Satoshi Morita
Norikazu Masuda

Background This study aimed to investigate whether schedule modification is safe and effective in patients intolerant to the standard eribulin dose and schedule.

Keywords:

Prospective cohort study
General surgery
Eribulin
Medicine
Metastatic breast cancer
Oncology
Internal medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations